Stolper Co Boosts Holdings in Pfizer Inc. (NYSE:PFE)

Stolper Co boosted its position in shares of Pfizer Inc. (NYSE:PFEFree Report) by 9.1% in the first quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 48,349 shares of the biopharmaceutical company’s stock after acquiring an additional 4,036 shares during the period. Stolper Co’s holdings in Pfizer were worth $1,342,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. Rathbones Group PLC raised its holdings in shares of Pfizer by 29.1% in the third quarter. Rathbones Group PLC now owns 635,548 shares of the biopharmaceutical company’s stock worth $21,081,000 after buying an additional 143,299 shares during the last quarter. V Square Quantitative Management LLC raised its holdings in shares of Pfizer by 1,394.1% in the third quarter. V Square Quantitative Management LLC now owns 5,827 shares of the biopharmaceutical company’s stock worth $193,000 after buying an additional 5,437 shares during the last quarter. Provence Wealth Management Group raised its holdings in shares of Pfizer by 15.2% in the third quarter. Provence Wealth Management Group now owns 8,659 shares of the biopharmaceutical company’s stock worth $287,000 after buying an additional 1,143 shares during the last quarter. Estabrook Capital Management raised its holdings in shares of Pfizer by 8.5% in the third quarter. Estabrook Capital Management now owns 333,217 shares of the biopharmaceutical company’s stock worth $11,053,000 after buying an additional 26,208 shares during the last quarter. Finally, Brandes Investment Partners LP raised its holdings in shares of Pfizer by 4.2% in the third quarter. Brandes Investment Partners LP now owns 2,957,423 shares of the biopharmaceutical company’s stock worth $98,098,000 after buying an additional 119,009 shares during the last quarter. Hedge funds and other institutional investors own 68.36% of the company’s stock.

Wall Street Analyst Weigh In

A number of research firms have issued reports on PFE. BMO Capital Markets reaffirmed an “outperform” rating and issued a $36.00 price target (up previously from $33.00) on shares of Pfizer in a report on Thursday, May 2nd. Guggenheim initiated coverage on shares of Pfizer in a report on Friday, February 23rd. They issued a “buy” rating and a $36.00 price target for the company. Morgan Stanley raised their target price on shares of Pfizer from $28.00 to $29.00 and gave the stock an “equal weight” rating in a report on Thursday, May 2nd. Cantor Fitzgerald reissued an “overweight” rating and set a $45.00 target price on shares of Pfizer in a report on Monday. Finally, Argus cut shares of Pfizer from a “buy” rating to a “hold” rating in a report on Friday, March 22nd. Ten analysts have rated the stock with a hold rating and six have given a buy rating to the company’s stock. According to MarketBeat, Pfizer presently has an average rating of “Hold” and an average target price of $35.86.

Read Our Latest Research Report on Pfizer

Pfizer Stock Performance

PFE stock traded up $0.47 during midday trading on Thursday, hitting $27.88. 17,787,555 shares of the stock traded hands, compared to its average volume of 41,137,203. The firm has a market cap of $157.98 billion, a P/E ratio of -460.76, a PEG ratio of 1.08 and a beta of 0.70. The company has a debt-to-equity ratio of 0.66, a current ratio of 1.05 and a quick ratio of 0.78. The stock’s fifty day simple moving average is $27.61 and its 200-day simple moving average is $27.73. Pfizer Inc. has a 1-year low of $25.20 and a 1-year high of $39.24.

Pfizer (NYSE:PFEGet Free Report) last released its quarterly earnings results on Wednesday, May 1st. The biopharmaceutical company reported $0.82 EPS for the quarter, beating the consensus estimate of $0.56 by $0.26. The company had revenue of $14.88 billion for the quarter, compared to analyst estimates of $13.87 billion. Pfizer had a negative net margin of 0.56% and a positive return on equity of 8.64%. The firm’s revenue was down 19.5% on a year-over-year basis. During the same quarter last year, the business earned $1.23 earnings per share. On average, analysts expect that Pfizer Inc. will post 2.38 earnings per share for the current year.

Pfizer Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Friday, June 14th. Stockholders of record on Friday, May 10th were given a $0.42 dividend. The ex-dividend date of this dividend was Thursday, May 9th. This represents a $1.68 annualized dividend and a dividend yield of 6.03%. Pfizer’s dividend payout ratio (DPR) is -2,799.53%.

About Pfizer

(Free Report)

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.

See Also

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFEFree Report).

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.